Overview
PriMeric — It’s hard to justify not using it.
The main active ingredient in PriMeric is curcumin — the
yellow substance in the turmeric spice. Curcumin has a long history
of medicinal use in India and China, and in recent years has
become a focus of medical research because of its remarkable
effects on inflammation, viruses, protein handling, and on
free-radical damage to the body.
LifeLink’s PriMeric formula includes two bioavailability
enhancers — quercetin and piperine — which not only dramatically
increase curcumin’s otherwise poor absorption but also slow its
metabolic conversion to inactive substances, giving it a much
longer opportunity to act.
Four medical conditions for which curcumin seems to hold especially exciting prospects are:
- Alzheimer’s Disease
- Parkinson’s Disease
- Cystic fibrosis
- Epstein-Barr Virus infections, which lie behind such diseases as chronic fatigue syndrome, infectious mononucleosis, multiple
sclerosis, Burkitt’s lymphoma, Hodgkin lymphoma, and numerous other cancers and lymphomas.
Studies of curcumin have also reported beneficial effects on the following medical conditions:
- High cholesterol levels
- Free radical damage to tissues
- Diabetic cataracts, wounds, pancreatic damage
- Rheumatoid arthritis
- Inflammatory bowel disease, Crohn’s Disease
- Psoriasis
- Cancer
- Atherosclerosis
- Inherited peripheral neuropathies
- Liver damage by chemicals and drugs
- Microbial infections.
The recommended dose for this supplement is 3 capsules per day (1000 mg/day of curcumin). Lower doses may be beneficial for
general well-being, but higher doses are used in clinical trials for patients with specific ailments, such as cancer.
Considering the wide range of beneficial actions of this supplement and its well-established safety, it ranks as one of the
supplement world’s smartest choices.
Read PriMeric Monograph
The main active ingredient in PriMeric is curcumin — the yellow substance in the turmeric spice. Curcumin has a long history
of medicinal use in India and China, and in recent years has become a focus of medical research because of its remarkable effects on such processes as tissue
damage by free radicals, inflammation, viral replication, and protein handling.
Curcumin
normally is absorbed poorly from the human digestive tract. Less than
1% of the curcumin one consumes actually makes it into the bloodstream,
and the liver rapidly destroys most of this. To eliminate this problem,
LifeLink formulated PriMeric with two bioavailability enhancers —
quercetin and piperine — which not only dramatically increase the
absorption but also slow the metabolic conversion of curcumin to
inactive substances, giving it a much longer opportunity to act.
What we can’t tell you
In
the U.S. and some other industrialized countries, government agencies
like the U.S. Food and Drug Administration have adopted censorship as a
method for intensifying their control over the supplement industry and
its customers. Thus, FDA regulations prohibit us from telling you that
any of our products are effective as medical treatments, even if they are, in fact, effective.
Accordingly, we will limit our discussion of PriMeric to a brief summary of recent curcumin research, and let you draw your
own conclusions about what medical conditions it may be effective in treating.
Since 1970, when curcumin first attracted the interest of scientific medical researchers, studies of curcumin have reported
suppressive effects for the following medical conditions:
- High serum cholesterol levels
- Free radical damage to tissues
- Diabetic cataracts
- Diabetic damage to pancreatic insulin-producing cells
- Diabetic wounds
- Rheumatoid arthritis
- Inflammatory bowel disease, Crohn’s Disease
- Psoriasis
- Cancer
- Atherosclerosis
- Inherited peripheral neuropathies
- Liver damage by chemicals and drugs
- Microbial infections
Anyone
suffering from any of these ailments will probably find encouragement
in the fact that medical research has identified curcumin as a possible
aid. We want to single out four other medical conditions for which
curcumin seems to hold especially exciting prospects:
- Alzheimer’s Disease
- Parkinson’s Disease
- Cystic fibrosis
- Ailments related to Epstein-Barr Virus
Curcumin and Alzheimer’s Disease
Curcumin has shown pronounced anti-Alzheimer’s effects in animal studies and is being tested in human clinical trials. Its ability to disassemble the brain plaques (amyloid protein) that characterize Alzheimer’s Disease has led researchers to say that it has the potential both to prevent the condition and to reverse it.
Parkinson’s Disease
Although the symptoms of Parkinson’s Disease differ from those of Alzheimer’s Disease, the causes are thought to have much
in common. Both diseases involve the formation of protein plaques in the brain, the trapping of metal atoms in the plaques, the production of destructive free radicals by the metal atoms, and the formation of protein pores in the membranes of nerve cells.
In
view of this similarity between the two diseases, and considering that
curcumin has shown anti-Alzheimer’s effects, it is not surprising that
it has also shown neuroprotective effects in biochemical models and in
a rat model of Parkinson’s.
Cystic fibrosis
Cystic
fibrosis is a disease that is usually caused by a faulty protein in
cells of respiratory and digestive tissues. The protein, called ‘CFTR’,
is normally made inside cells and then transported and installed in the
outer cell membranes, where it regulates the movement of salt molecules
in and out of the cells. The defective CFTR proteins produced by most
cystic fibrosis patients are quickly destroyed by scavenger mechanisms,
leaving cells without the ability to regulate the movement of salt. The
resulting disruption causes secretions in these tissues to become too
viscous.
In 2004 it was announced by researchers at
Yale University that mice with cystic fibrosis symptoms caused by
faulty CFTR proteins could be successfully treated with curcumin, taken
orally.
One might have expected this report to have been quickly followed by
clinical trials to test the concept in humans, with results within a
few months. But those who know how the medical world actually behaves
nowadays will not be surprised to learn that nothing of the sort took
place — instead, many research groups tried to test the concept in
tissue culture. Some obtained positive results, some negative, turning
a simple question into a contentious issue. The Cystic Fibrosis Foundation did fund a clinical trial, but as of April 2006, two years after the Yale group’s published
report, the trial has yet to progress beyond basic safety studies; the question of efficacy has not been addressed.
Some cystic fibrosis patients, however, were unwilling to wait years and years for the medical world to get its act together.
They immediately began trying curcumin treatments on their own. The results varied from excellent to poor.
Since many of these self-experiments used curcumin without
bioavailability enhancers, and none of them seem to have used both
piperine and quercetin as enhancers, it is possible that curcumin’s low
bioavailability index may account for the variable results.
Curcumin and Epstein-Barr Virus
Recent
scientific studies provide evidence that turmeric can inhibit the
activation of Epstein-Barr Virus — a herpes-family virus thought to be
a cause or contributor to many diseases, such as Burkitt’s lymphoma,
infectious mononucleosis, Hodgkin lymphoma, chronic fatigue syndrome,
multiple sclerosis, and numerous cancers and lymphomas.
Conclusion
Are
curcumin supplements effective for treating or preventing Alzheimer’s
or Parkinson’s Diseases, Cystic Fibrosis, or the other ailments
mentioned in this article? We aren’t allowed to tell you, so you should
take a look at some of the references cited here, and then decide for
yourself.
References
[1] Curcuma longa - Turmeric - Monograph Alternative Medicine Review, Sept, 2001
[2] Effect of curcumin on serum and liver cholesterol levels in the rat. J Nutr. 1970 Nov;100(11):1307-15 Rao DS, Sekhara NC, Satyanarayana MN, Srinivasan M
[3] Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2092-9 Suryanarayana P, Saraswat M, Mrudula T, Krishna TP, Krishnaswamy K, Reddy GB
[4] Protection of pancreatic beta-cell by the potential antioxidant bis-o-hydroxycinnamoyl methane, analogue of natural curcuminoid
in experimental diabetes. J Pharm Pharm Sci. 2003 Sep-Dec;6(3):327-33 Srivivasan A, Menon VP, Periaswamy V, Rajasekaran KN
[5] Curcumin enhances wound healing in streptozotocin induced diabetic rats and genetically diabetic mice. Wound Repair Regen. 1999 Sep-Oct;7(5):362-74 Sidhu GS, Mani H, Gaddipati JP, Singh AK, Seth P, Banaudha KK, Patnaik GK, Maheshwari RK
[6] Traditional Indian systems of medicine. Ann Acad Med Singapore. 2000 Jan;29(1):37-41 Lodha R, Bagga A.
[7] Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005 Nov;50(11):2191-3 Holt PR, Katz S, Kirshoff R.
[8] The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review. Arch Gerontol Geriatr. 2002 Feb;34(1):37-46 Miquel J, Bernd A, Sempere JM, Diaz-Alperi J, Ramirez A
[9] Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003 Jan-Feb;23(1A):363-98 Aggarwal BB, Kumar A, Bharti AC
[10] Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum
and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):120-5 Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ
[11a] Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. [abstract] J Physiol Pharmacol. 2005 Dec;56(4):627-35 Olszanecki R, Jawien J, Gajda M, Mateuszuk L, Gebska A, Korabiowska M, Chlopicki S, Korbut R
[11b] Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. [PDF, 213KB] J Physiol Pharmacol. 2005 Dec;56(4):627-35 Olszanecki R, Jawien J, Gajda M, Mateuszuk L, Gebska A, Korabiowska M, Chlopicki S, Korbut R
[12] Curcumin
treatment abrogates endoplasmic reticulum retention and
aggregation-induced apoptosis associated with neuropathy-causing myelin
protein zero-truncating mutants. Am J Hum Genet. 2005 Nov;77(5):841-50. Epub 2005 Sep 30 Khajavi M, Inoue K, Wiszniewski W, Ohyama T, Snipes GJ, Lupski JR
[13] [Curcuma xanthorrhiza (Java tumeric) in clinical use][Article in German] Fortschr Med. 1996 Sep 30;114(27):349-50 Hentschel C, Eglau MC, Hahn EG
[14] A review of antioxidants and Alzheimer's disease. Ann Clin Psychiatry. 2005 Oct-Dec;17(4):269-86 Frank B, Gupta S
[15] Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005 Feb 18;280(7):5892-901. Epub 2004 Dec 7 Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM
[16] A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res. 2005 Apr;2(2):131-6 Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL
[17] Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J Alzheimers Dis. 2004 Aug;6(4):367-77; discussion 443-9 Baum L, Ng A
[18] Amyloid Pore Section Website of P.T. Lansbury at Harvard University
[19] The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol. 2005 Dec;146(8):1041-59 Gaeta A, Hider RC
[20] Curcumin inhibits dose-dependently and time-dependently neuroglial cell proliferation and growth. Neuro Endocrinol Lett. 2003 Dec;24(6):469-73 Ambegaokar SS, Wu L, Alamshahi K, Lau J, Jazayeri L, Chan S, Khanna P, Hsieh E, Timiras PS
[21] Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a
6-OHDA model of Parkinson's disease. Free Radic Res. 2005 Oct;39(10):1119-25 Zbarsky V, Datla KP, Parkar S, Rai DK, Aruoma OI, Dexter DT
[22] Up-regulation of astrocyte cyclooxygenase-2, CCAAT/enhancer-binding protein-homology protein, glucose-related protein 78,
eukaryotic initiation factor 2 alpha, and c-Jun N-terminal kinase by a neurovirulent murine retrovirus. J Neurovirol. 2005 Apr;11(2):166-79 Kim HT, Qiang W, Liu N, Scofield VL, Wong PK, Stoica G
[23] Curcumin
protects PC12 cells against 1-methyl-4-phenylpyridinium ion-induced
apoptosis by bcl-2-mitochondria-ROS-iNOS pathway(*). Apoptosis. 2006 Mar 13; [Epub ahead of print] Chen J, Tang XQ, Zhi JL, Cui Y, Yu HM, Tang EH, Sun SN, Feng JQ, Chen PX
[24] Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science. 2004 Apr 23;304(5670):600-2 Egan ME, Pearson M, Weiner SA, Rajendran V, Rubin D, Glockner-Pagel J, Canny S, Du K, Lukacs GL, Caplan MJ
[25] Correction of the CF defect by curcumin: hypes and disappointments. Bioessays. 2005 Jan;27(1):9-13 Mall M, Kunzelmann K
[26] Cystic Fibrosis Foundation website
[27] ‘Curcumin for Cystic Fibrosis’ forum on Yahoo
[28] Inhibitory
effect of herbal remedies on
12-O-tetradecanoylphorbol-13-acetate-promoted Epstein-Barr virus early
antigen activation. Pharmacol Res 2002 Mar;45(3):213-220 Kapadia GJ, Azuine MA, Tokuda H, Hang E, Mukainaka T, Nishino H, Sridhar R
